{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:15:06Z","timestamp":1790835306183,"version":"4.1.0"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nIntroduction The atypical antipsychotic quetiapine is known to induce weight gain and other metabolic complications. The underlying mechanisms are multifactorial and poorly understood with almost no information on the effect of dosage. Concerns were thus raised with the rise in low-dose quetiapine off-label prescription (i.\u2009e.,&lt;150\u2009mg\/day).<\/jats:p><jats:p>\nMethods In this study, we evaluated the influence of quetiapine dose for 474 patients included in PsyMetab and PsyClin studies on weight and metabolic parameter evolution. Weight, blood pressure, lipid, and glucose profiles were evaluated during a follow-up period of 3 months after treatment initiation.<\/jats:p><jats:p>\nResults Significant dose-dependent metabolic alterations were observed. The daily dose was found to influence weight gain and increase the risk of undergoing clinically relevant weight gain (\u22657% from baseline). It was also associated with a change in plasma levels of cholesterol (total cholesterol, LDL cholesterol, and HDL cholesterol) as well as with increased odds of developing hypertriglyceridemia, as well as total and LDL hypercholesterolemia. No impact of a dose increase on blood pressure and plasma glucose level was observed.<\/jats:p><jats:p>\nDiscussion The dose-dependent effect highlighted for weight gain and lipid alterations emphasizes the importance of prescribing the minimal effective dose. However, as the effect size of a dose increase on metabolic worsening is low, the potential harm of low-dose quetiapine should not be dismissed. Prescriptions must be carefully evaluated and regularly questioned in light of side effect onset.<\/jats:p>","DOI":"10.1055\/a-1525-2820","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T22:40:22Z","timestamp":1628894422000},"page":"279-286","source":"Crossref","is-referenced-by-count":24,"title":["Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study"],"prefix":"10.1055","volume":"54","author":[{"given":"C\u00e9line","family":"Dubath","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Piras","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Gholam","sequence":"additional","affiliation":[{"name":"Center for Psychiatric Epidemiology and Psychopathology, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermine","family":"Laaboub","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Grosu","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman","family":"Sentissi","sequence":"additional","affiliation":[{"name":"Adult Psychiatry Division, Department of Psychiatry, University Hospital of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Gamma","sequence":"additional","affiliation":[{"name":"Les Toises Psychiatry and Psychotherapy Center, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Solida","sequence":"additional","affiliation":[{"name":"Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"von Gunten","sequence":"additional","affiliation":[{"name":"Service of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Conus","sequence":"additional","affiliation":[{"name":"Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin B.","family":"Eap","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland"},{"name":"School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland"},{"name":"Center for Research and Innovation in Clinical Pharmaceutical Sciences, University of Lausanne, Lausanne, Switzerland"},{"name":"Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113, 383, 368 controls","volume":"16","author":"C U Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: A systematic review and meta-analysis","volume":"72","author":"E R Walker","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/eip.12251","article-title":"Antipsychotic-induced weight gain in first-episode psychosis patients: A meta-analysis of differential effects of antipsychotic medications","volume":"10","author":"C Tek","year":"2016","journal-title":"Early Interv Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14740338.2020.1713091","article-title":"Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis","volume":"19","author":"B B Barton","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1517\/14740338.2015.974549","article-title":"Weight gain and antipsychotics: A drug safety review","volume":"14","author":"R Musil","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pnpbp.2018.01.004","article-title":"Atypical antipsychotics, insulin resistance and weight; A meta-analysis of healthy volunteer studies","volume":"83","author":"K J Burghardt","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejphar.2018.12.003","article-title":"Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives","volume":"844","author":"R Singh","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14740338.2019.1674809","article-title":"Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia","volume":"18","author":"W Marteene","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.4088\/JCP.13r08558","article-title":"Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: A systematic review and meta-analysis","volume":"75","author":"J M Gierisch","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"V Simon","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis","volume":"306","author":"A R Maher","year":"2011","journal-title":"J Am Med Assoc"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.4088\/JCP.v66n1203","article-title":"Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies","volume":"66","author":"L Citrome","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamainternmed.2016.3309","article-title":"Off-label use of quetiapine in medical inpatients and postdischarge","volume":"176","author":"T C Lee","year":"2016","journal-title":"JAMA Intern Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e010861","DOI":"10.1136\/bmjopen-2015-010861","article-title":"Quetiapine use in adults in the community: A population-based study in Alberta, Canada","volume":"6","author":"D Duncan","year":"2016","journal-title":"BMJ Open"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/PRA.0000000000000085","article-title":"Evolution of first-generation and second-generation antipsychotic prescribing patterns in Belgium between 1997 and 2012: A population-based study","volume":"21","author":"M Morrens","year":"2015","journal-title":"J Psychiatr Pract"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e006135","DOI":"10.1136\/bmjopen-2014-006135","article-title":"Prescribing of antipsychotics in UK primary care: A cohort study","volume":"4","author":"L Marston","year":"2014","journal-title":"BMJ Open"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4088\/JCP.09r05535gre","article-title":"Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics","volume":"72","author":"K Gao","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1345\/aph.1Q697","article-title":"Safety of low doses of quetiapine when used for insomnia","volume":"46","author":"H V Coe","year":"2012","journal-title":"Ann Pharmacother"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.9740\/mhc.2016.11.308","article-title":"Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review","volume":"6","author":"C N Carr","year":"2016","journal-title":"Ment Health Clin"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4088\/JCP.10m06194","article-title":"A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder","volume":"73","author":"W G Honer","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0269881119885918","article-title":"Effects of long-term antipsychotics treatment on body weight: A population-based cohort study","volume":"34","author":"J C Bazo-Alvarez","year":"2020","journal-title":"J Psychopharmacol"},{"key":"ref23","first-page":"81","article-title":"Evaluation of cardiometabolic risk in a large psychiatric cohort and comparison with a population-based sample in Switzerland","author":"C Dubath","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"ref24","first-page":"1994","article-title":"Suivi du syndrome m\u00e9tabolique induit par les antipsychotiques atypiques: Recommandations et perspectives pharmacog\u00e9n\u00e9tiques","volume":"4","author":"E Choong","year":"2008","journal-title":"Rev Med Suisse"},{"key":"ref25","volume-title":"IDF Consensus Worldwide Definition of the Metabolic Syndrome","year":"2006"},{"key":"ref26","volume-title":"Seroquel (quetiapine fumarate)\u2014FDA","year":"1997"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e1417","DOI":"10.4088\/JCP.14m09358","article-title":"Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment","volume":"76","author":"F Vandenberghe","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jacl.2017.10.002","article-title":"Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and new onset dyslipidemia","volume":"12","author":"A Delacretaz","year":"2018","journal-title":"J Clin Lipidol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/cells8111336","article-title":"Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain","volume":"8","author":"D Grajales","year":"2019","journal-title":"Cells"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.yic.0000188213.46667.f1","article-title":"Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations","volume":"21","author":"W Aichhorn","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1055\/s-0043-109695","article-title":"Relationship between daily dose, serum concentration, and clinical response to quetiapine in children and adolescents with psychotic and mood disorders","volume":"50","author":"L Albantakis","year":"2017","journal-title":"Pharmacopsychiatry"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1525-2820.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T23:32:58Z","timestamp":1636414378000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1525-2820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":30,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2021,11,8]]},"published-print":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1525-2820","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]}}}